Table 2.
Patient cohort used for the cross-sectional validation studies.
| African-American cohort | Caucasian cohort | |||||
|---|---|---|---|---|---|---|
| Active LN | Inactive SLE | Healthy control | Active LN | Inactive SLE | Healthy control | |
| N = 14 | N = 19 | N = 14 | N = 13 | N = 28 | N = 7 | |
| Age (years) | 31.2 ± 8.6 | 33.1 ± 10.3 | 32.2 ± 5.1 | 44.8 ± 10.8 | 48.9 ± 10.7 | 50.1 ± 5.7 |
| Female, no. (%) | 14 (100%) | 19 (100%) | 14(100%) | 13 (100%) | 28(100%) | 7(100%) |
| SLEDAI, median (IQR) | 11(10–14) | 2 (0–4) | N/A | 12(10–12) | 0 (0–0) | N/A |
| rSLEDAI, median (IQR) | 8 (8–12) | 0 (0–0) | N/A | 8 (8–8) | 0 (0–0) | N/A |
| PGA, median (IQR) | 2.1 (1.9–2.5) | 1 (0.5–1.2) | N/A | 1.5 (1.5–1.8) | 0.5 (0–0.6) | N/A |
| Protein:Cr ratio (mg/mg) | 2.7 ± 1.5 | 0.4 ± 0.3 | N/A | 1.3 ± 1.0 | 0.2 ± 0.1 | N/A |
| eGFR (ml/min/1.73 m2) | 121 ± 40 | 100 ± 45 | N/A | 83 ± 24 | 77 ± 26 | N/A |
| Serum creatinine (mg/dl) | 0.8 ± 0.3 | 1 ± 0.5 | N/A | 0.9 ± 0.2 | 0.9 ± 0.3 | N/A |
| Anti-dsDNA+ve/total tested | 7/14 | 6/17 | N/A | 7/13 | 1/28 | N/A |
| Hypocomplementemia/total | 5/13 | 5/19 | N/A | 7/13 | 4/28 | N/A |
| Concurrent medication use, n (%) | ||||||
|---|---|---|---|---|---|---|
| Prednisone | 10 (71%) | 15 (79%) | N/A | 10 (77%) | 9 (32%) | N/A |
| Immunosuppressants | 12 (86%) | 12 (63%) | N/A | 7 (54%) | 16 (57%) | N/A |
| Plaquenil | 14 (100%) | 18 (95%) | N/A | 8 (62%) | 23 (82%) | N/A |
| NSAID | 3 (21%) | 2 (11%) | N/A | 3 (23%) | 1 (4%) | N/A |
| Anti-hypertensives | 10 (71%) | 12 (63%) | N/A | 12 (92%) | 23 (82%) | N/A |
| Diuretic | 4 (29%) | 5 (26%) | N/A | 3 (23%) | 4 (14%) | N/A |
| ACE inhibitor or ARB | 8 (57%) | 11 (58%) | N/A | 8 (62%) | 18 (64%) | N/A |
| Statin | 3 (21%) | 3 (16%) | N/A | 3 (23%) | 16 (57%) | N/A |
Anti-dsDNA+ve refers to number of subjects who were positive for anti-dsDNA antibodies.
Source data are provided as a Source Data file.